EGFR and non-small cell lung carcinoma: Additionally, we found that not only 2nd-line osimertinib treatment but also ≥3rd-line osimertinib treatment provided sufficient efficacies in advanced and recurrence EGFR-mutant NSCLC patients harboring T790M mutation after experiencing drug resistance to first- and second-generation EGFR-TKIs.